Business
Repligen Reports First Quarter 2025 Financial Results
Revenue of $169 million, year-over-year increase of 10% as reported and 14% organic non-COVID gro...
About this update from Regenera Insights Inc.
[{"type":"text","content":"Repligen Reports First Quarter 2025 Financial Results\n\n\n\n\n\n Revenue of $169 million, year-over-year increase of 10% as reported and 14% organic non-COVID growth\n \n\n\n\n Orders increased sequentially and high-teens year-over-year\n \n\n\n\n Adjusted operating income increased 72% year-over-year\n \n\n\n\n Reiterates 2025 full year organic revenue guidance of 9.5% - 13.5%\n \n\n\n\n WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter of 2025, covering the three-month period ended March 31, 2025. The company is also providing updated financial guidance for the full year 2025.\n \n\n Olivier Loeillot, President and Chief Executive Officer of Repligen said, “We had a strong start to the year with $169 million of revenue, which represented 14% organic non-COVID growth and helped drive meaningful adjusted operating margin expansion. Total orders grew nearly 20%, with all four franchises growing double-digits, highlighting the momentum in our business. As a result, we are confident in our organic growth outlook for the full year. Strategically, we strengthened our Analytics franchise with the acquisition of 908’s bioprocessing portfolio. Finally, we are working to navigate through the current economic environment and at this point in time, we see minimal impact from tariffs on our EPS.”\n \n\n\n Q1 2025 BUSINESS HIGHLIGHTS\n \n\n\n\n\n Biopharma and consumables.\n \n Revenues for both biopharma and consumables increased greater than 20% year-over-year, reaching record levels excluding COVID.\n \n\n\n M&A.\n \n Closed acquisition of 908 Devices’ bioprocessing portfolio, complementing and strengthening our process analytical technology (PAT) offering with upstream capabilities.\n \n\n\n New products.\n \n Launched CTech™ SoloVPE® Plus System, our next generation UV-based Variable Pathlength Technology system offering unparalleled accuracy, speed and ease-of-use.\n \n\n\n\n\n FINANCIAL PERFORMANCE\n \n\n\n Q1 2025 financial performance (compared to prior year periods except as noted).\n \n\n\n All adjusted figures are non-GAAP and, except for earnings per share, are rounded to the nearest million, and are reconciled in the table...